.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
N-MOmentum was a pivotal randomized phase 2/3 trial evaluating inebilizumab, a CD19-directed B-cell-depleting monoclonal antibody, in neuromyelitis optica spectrum disorder. Adults with NMOSD were randomised to inebilizumab or placebo and followed for protocol-defined attacks. The active-treatment group experienced fewer attacks, providing evidence that B-cell depletion can meaningfully alter the disease course. Subsequent analyses showed a lower risk of confirmed disability progression and more favourable modified Rankin outcomes with inebilizumab. The results are clinically important because NMOSD disability is largely attack-driven; preventing relapses can therefore be as important as treating residual symptoms after an attack. For HCPs, the study underscores the need for early diagnosis and long-term relapse prevention, especially in AQP4-positive disease. Treatment selection should account for prior immunotherapy, infection risk, vaccination and the logistics of ongoing therapy. The trial also strengthens the broader principle of mechanism-based treatment in neuroimmunology: identifying the immune pathway driving disease can directly inform treatment choice.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
N-MOmentum was a pivotal randomized phase 2/3 trial evaluating inebilizumab, a CD19-directed B-cell-depleting monoclonal antibody, in neuromyelitis optica spectrum disorder. Adults with NMOSD were randomised to inebilizumab or placebo and followed for protocol-defined attacks. The active-treatment group experienced fewer attacks, providing evidence that B-cell depletion can meaningfully alter the disease course. Subsequent analyses showed a lower risk of confirmed disability progression and more favourable modified Rankin outcomes with inebilizumab. The results are clinically important because NMOSD disability is largely attack-driven; preventing relapses can therefore be as important as treating residual symptoms after an attack. For HCPs, the study underscores the need for early diagnosis and long-term relapse prevention, especially in AQP4-positive disease. Treatment selection should account for prior immunotherapy, infection risk, vaccination and the logistics of ongoing therapy. The trial also strengthens the broader principle of mechanism-based treatment in neuroimmunology: identifying the immune pathway driving disease can directly inform treatment choice.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
